OraSure Technologies Lands $8.6M Contract to Develop Ebola Diagnostic

Diagnostic testing company, OraSure Technologies (Nasdaq: OSUR) has been awarded an $8.6 million contract by the Biomedical Advanced Research and Development Authority  (BARDA) to develop a second generation Ebola test.

The test will be developed on the company’s OraQuick® platform and is expected to feature improved sensitivity, increased shelf life, new chemistry and more automation when compared to the de novo FDA-authorized test.

 Highlights

  • OraSure’s OraQuick® Ebola Rapid Antigen test is the only test today with a de novo authorization from the FDA;
  • The test has been used extensively for Ebola cadaver testing in Africa with results available in 30 minutes;
  • The project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority.

OraSure has partnered with the US government to counter some of the largest public health challenges worldwide.

Share This Article

 

About the Author

OraSure Technologies Lands $8.6M Contract to Develop Ebola Diagnostic

Editor Prism MarketView